Scilex Holding Company Common Stock
$5.37
$0.20 (+3.87%)
$5.22Day Range$5.60
Key Statistics
Market Cap
$37.78M
Shares Outstanding
7.0M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Nov 11, 2022
Round Lot
100
Locale
US
Trading Data
Day Open
$5.22
Day High
$5.60
Day Low
$5.22
Volume
40.3K
VWAP
$5.40
Prev Close
$5.17
Transactions
--
Acc. Volume
--
About Scilex Holding Company Common Stock
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 283634 employees960 SAN ANTONIO ROAD, PALO ALTO, CA, 94303(650) 516-4310IPO Nov 11, 2022US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001820190
- Composite FIGI
- BBG00YJTT4L8
- Share Class FIGI
- BBG00YJTT5F2
- Ticker Root
- SCLX
- SIC Code
- 2836
About Scilex Holding Company Common Stock (SCLX) Stock
Scilex Holding Company Common Stock (SCLX) closed the 2026-09-17 session at $5.37, up 3.87% versus the previous close (+0.20). The stock opened at $5.22 and traded between $5.22 and $5.60 during that session. Session trading volume was 40K shares. The volume-weighted average price (VWAP) is $5.40.
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
Scilex Holding Company Common Stock has a market capitalization of $37.8 million. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. SCLX is listed on the XNAS exchange. The company employs approximately 34 people. Scilex Holding Company Common Stock is headquartered in PALO ALTO, CA. The recorded listing date is 2022-11-11.
On this page you can find market SCLX stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.